Navigation Links
Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
Date:6/13/2008

HAE:TSX

MONTREAL, June 13 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announced today that Joseph Galli, Chairman and Chief Executive Officer, will present Haemacure and give an update on the Company's major milestone achievements at the Bio International Convention - The Global Event for Biotechnology. The presentation will take place on Thursday, June 19th, at 1:30 pm (PDT), in Room 3, of the San Diego Convention Centre.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
3. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
4. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
5. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
8. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
9. Haemacure financing receives shareholder consent - Series B Warrants are amended
10. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... (PRWEB) May 27, 2015 SIMpalm ... helped its client to launch an Android version for ... merchants to accept credit, debit and ACH payments on ... Google Play at: https://play.google.com/store/apps/details?id=com.simpalm.paymentgateway . The iOS version ... has been recently updated by SIMpalm. , Forte ...
(Date:5/27/2015)... Get Tested Coachella Valley , a ... of HIV, will recognize its most influential, passionate and ... Ambassador Awards, to be held on Twitter on June ... first for public health campaigns, the online awards ceremony ... influencers for breaking down stigma, spreading awareness and educating ...
(Date:5/27/2015)... According to research conducted by Dr. Huay-Zong ... Dallas some migraine patients have an increased likelihood of ... apparently also have some shared risk factors -- particularly ... a history of diabetes and/or smoking. Both conditions were ... in particular was less common in Hispanics. , ...
(Date:5/27/2015)... The Advanced Fertility Center of Chicago announces ... business to better serve the needs of couples in Chicagoland. ... on the Northwest side of the city at 4920 North ... by calling the Chicago office at (773) 794–1818. This ... of Chicago. The other 2 offices are in Gurnee ...
(Date:5/26/2015)... 27, 2015 Carey Danis & ... testosterone gel lawsuit . The suit pertains to AndroGel, ... was filed in late April 2015, and a court ... Illinois federal court in mid-May.¹ , Testosterone gel lawsuits ... the Northern District of Illinois. The multidistrict litigation (MDL) ...
Breaking Medicine News(10 mins):Health News:Forte Payment System Launches Android Version of Payment App 2Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 2Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 2Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 4Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2
... , THURSDAY, Sept. 29 (HealthDay News) -- One-quarter of American ... to new research from the U.S. Agency for Healthcare Research ... blood pressure, also known as hypertension, 29 percent were black ... federal agency noted in its Sept. 27 News and ...
... , THURSDAY, Sept. 29 (HealthDay News) -- Campus-wide smoking bans ... habit, new research suggests. The finding stems from a ... a ban and one without. "Although we haven,t pinpointed ... most to the positive changes in students, smoking rates, having ...
... DCThrough the identification of a gene,s impact on a ... continue to make progress in understanding the mechanics ... of white matter, known as myelination. The study, published ... of The Journal of Neuroscience , identified Sox17 ...
... might think, cancer and diabetes appear to have some biology in ... the Cell Press journal, Cell, a pathway that initially ... also influences the odds that mice develop or resist diabetes. ... Lin28b become more sensitive to insulin and less prone to diabetes ...
... , HOUSTON, Sept. 29, 2011 Hormone researchers at ... on providing long-term treatment options for diabetes, obesity and ... naturally occurring estrogen. They now believe that ... body functions in both females and males. While estradiol ...
... 28, 2011 - (BRONX, NY) - People taking oral steroids ... severe vitamin D deficiency, according to a study of more ... Albert Einstein College of Medicine of Yeshiva University. Their ... of Clinical Endocrinology and Metabolism, suggest that physicians should more ...
Cached Medicine News:Health News:1 in 4 U.S. Adults Treated for High Blood Pressure: Report 2Health News:Campus Smoking Bans May Help College Students Quit 2Health News:Children's National researchers make breakthrough in understanding white matter development 2Health News:Children's National researchers make breakthrough in understanding white matter development 3Health News:Diabetes and cancer: A shared biological basis 2Health News:UH researchers explain hormonal role in glucose and fat metabolism 2Health News:Oral steroids linked to severe vitamin D deficiency in nationwide study 2
(Date:5/26/2015)... , May 26, 2015  AbbVie (NYSE: ... 3 GIFT-I study of its investigational, all-oral, interferon ... with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the ... Japan . 1 GIFT-I evaluated genotype ... Japanese patients, with and without cirrhosis, who were ...
(Date:5/26/2015)... Calif. , May 26, 2015 Thoratec ... mechanical circulatory support therapies to save, support and restore ... Goldman Sachs 36 th Annual Healthcare Conference on ... , President and Chief Executive Officer, will provide an ... Daylight time (5:00 p.m., Eastern Daylight Time). ...
(Date:5/26/2015)... , May 26, 2015  Amgen (NASDAQ: ... from the Phase 3 OPTiM study in the ... The data published in JCO , which ... American Society of Clinical Oncology (ASCO) in 2013 and ... in patients with unresected stage IIIB, IIIC or IV ...
Breaking Medicine Technology:AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 3Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 4Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 5Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 6Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 7Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 8
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
MRI curette, 8.5" overall length....
15" overall length, 5" handle....
10" overall length, 5" handle....
Medicine Products: